NSG 5240 ADVANCED PHARMACOLOGY MIDTERM EXAM PRACTICE | STUDY
GUIDE | TESTBANK | PRACTICE QUESTIONS & ANSWERS | EXAM PREPARATION |
LATEST UPDATE 2026/2027 | ADVANCED REVIEW | COMPREHENSIVE PRACTICE
EXAM
TABLE OF CONTENTS
1. Pharmacokinetics and Pharmacodynamics
2. Pharmacogenomics and Individualized Drug Therapy
3. Autonomic Nervous System Pharmacology
4. Cardiovascular Pharmacotherapy
5. Anticoagulants and Antiplatelet Agents
6. Endocrine Pharmacology
7. Antimicrobial Pharmacotherapy
8. Central Nervous System Pharmacology
9. Adverse Drug Reactions and Drug Interactions
10. Clinical Decision-Making, Monitoring, and Patient Safety
DESCRIPTION
This NSG 5240 Advanced Pharmacology Midterm Exam Practice Study Guide is
designed as a rigorous educational resource for graduate-level nursing pharmacology
preparation. It focuses on advanced application of pharmacokinetic and
pharmacodynamic principles, medication safety, drug interactions, adverse-effect
recognition, individualized therapy, and clinical decision-making. Questions
emphasize complex patient scenarios rather than simple memorization, requiring
learners to interpret laboratory findings, evaluate therapeutic responses, recognize
contraindications, prioritize interventions, and select appropriate pharmacologic
strategies. The practice set incorporates concepts commonly encountered in advanced
pharmacology coursework, including cardiovascular, endocrine, antimicrobial,
autonomic, and central nervous system agents. It is intended strictly as a study
resource to reinforce concepts and clinical reasoning for an NSG 5240 Advanced
Pharmacology midterm; it does not reproduce or claim to reproduce any actual
examination questions.
QUESTION 1.
,A 68-year-old patient with chronic kidney disease has been prescribed a medication
that is primarily eliminated unchanged by the kidneys. After several weeks of
therapy, the patient develops increasing sedation despite receiving the same dose
that was previously well tolerated. The patient's serum creatinine has increased
substantially from baseline. Which pharmacokinetic change most directly explains
the patient's increased drug exposure?
A. Increased hepatic first-pass metabolism
B. Decreased renal clearance resulting in an increased elimination half-life
C. Increased plasma protein binding causing accelerated elimination
D. Increased volume of distribution caused by reduced renal perfusion
🔴 Correct Answer: B. Decreased renal clearance resulting in an increased
elimination half-life
🔵 Explanation: Reduced renal clearance decreases the rate at which the drug is
eliminated, increasing its elimination half-life and allowing accumulation with
repeated dosing. This can produce progressive toxicity even when the prescribed dose
has not changed. Increased first-pass metabolism would generally reduce systemic
exposure, while increased protein binding does not explain the primary mechanism in
this scenario.
QUESTION 2.
A patient receiving warfarin for prevention of thromboembolism is started on a
medication that inhibits CYP2C9, the major enzyme responsible for metabolism of
the more potent S-enantiomer of warfarin. Three days later, the patient's INR has
increased substantially. Which interpretation is most appropriate?
A. The new medication has increased renal excretion of warfarin
B. Warfarin absorption has been reduced, producing a falsely elevated INR
C. The interaction is clinically insignificant because only the R-enantiomer is
pharmacologically active
D. CYP2C9 inhibition has reduced warfarin metabolism and increased anticoagulant
effect
🔴 Correct Answer: D. CYP2C9 inhibition has reduced warfarin metabolism and
increased anticoagulant effect
,🔵 Explanation: Inhibition of CYP2C9 decreases metabolism of S-warfarin, increasing
systemic exposure and anticoagulant activity. The resulting elevation in INR increases
bleeding risk and warrants prompt clinical assessment and medication-management
decisions. The interaction is clinically important because S-warfarin contributes
substantially to warfarin's anticoagulant effect.
QUESTION 3.
A patient with hypertension and heart failure is prescribed an ACE inhibitor. Two
weeks later, the patient reports persistent dry cough but has no dyspnea, fever, or
evidence of pulmonary infection. Which mechanism best explains this adverse
effect?
A. Increased pulmonary bradykinin concentration caused by ACE inhibition
B. Direct stimulation of bronchial β2 receptors
C. Increased pulmonary aldosterone secretion
D. Histamine depletion within airway mast cells
🔴 Correct Answer: A. Increased pulmonary bradykinin concentration caused by
ACE inhibition
🔵 Explanation: ACE participates in the degradation of bradykinin, so ACE inhibition
can increase bradykinin concentrations in pulmonary tissue and produce a persistent
nonproductive cough. The symptom is a recognized class effect and is not caused by
β2-receptor stimulation or histamine depletion. If clinically significant, an angiotensin
receptor blocker may be considered as an alternative because it does not directly
inhibit bradykinin degradation.
QUESTION 4.
A patient with type 2 diabetes mellitus and established atherosclerotic
cardiovascular disease has inadequate glycemic control despite metformin therapy.
The clinician is selecting an additional agent and wants to minimize hypoglycemia
while providing cardiovascular benefit. Which pharmacologic approach is most
appropriate?
A. Add a sulfonylurea as first-line cardiovascular risk-reduction therapy
B. Add a short-acting insulin secretagogue regardless of cardiovascular risk
, C. Consider a GLP-1 receptor agonist with demonstrated cardiovascular benefit
D. Discontinue metformin and initiate a thiazolidinedione solely to reduce
cardiovascular risk
🔴 Correct Answer: C. Consider a GLP-1 receptor agonist with demonstrated
cardiovascular benefit
🔵 Explanation: In appropriate patients with type 2 diabetes and established
atherosclerotic cardiovascular disease, certain GLP-1 receptor agonists have
demonstrated cardiovascular risk-reduction benefits and have a relatively low intrinsic
risk of hypoglycemia when used without insulin or insulin secretagogues.
Sulfonylureas can cause clinically significant hypoglycemia and do not provide the
same cardiovascular outcome advantages. Therapy must still be individualized
according to renal function, adverse-effect profile, comorbidities, and treatment goals.
QUESTION 5.
A patient receiving vancomycin for a serious bacterial infection has a declining
estimated glomerular filtration rate. The patient's antimicrobial therapy must
continue, but the clinician is concerned about accumulation and nephrotoxicity.
Which intervention best demonstrates pharmacokinetic-based medication
management?
A. Increase the dose because renal impairment reduces tissue penetration
B. Adjust the dosing regimen based on renal function and appropriate therapeutic
drug monitoring
C. Maintain the original regimen because vancomycin is eliminated primarily
through hepatic metabolism
D. Discontinue all laboratory monitoring once the patient becomes afebrile
🔴 Correct Answer: B. Adjust the dosing regimen based on renal function and
appropriate therapeutic drug monitoring
🔵 Explanation: Vancomycin is predominantly eliminated by the kidneys, so declining
renal function can increase exposure and toxicity risk. Dosing and monitoring should
be individualized using renal function and an appropriate pharmacokinetic
monitoring strategy. Maintaining the original regimen without reassessment may
GUIDE | TESTBANK | PRACTICE QUESTIONS & ANSWERS | EXAM PREPARATION |
LATEST UPDATE 2026/2027 | ADVANCED REVIEW | COMPREHENSIVE PRACTICE
EXAM
TABLE OF CONTENTS
1. Pharmacokinetics and Pharmacodynamics
2. Pharmacogenomics and Individualized Drug Therapy
3. Autonomic Nervous System Pharmacology
4. Cardiovascular Pharmacotherapy
5. Anticoagulants and Antiplatelet Agents
6. Endocrine Pharmacology
7. Antimicrobial Pharmacotherapy
8. Central Nervous System Pharmacology
9. Adverse Drug Reactions and Drug Interactions
10. Clinical Decision-Making, Monitoring, and Patient Safety
DESCRIPTION
This NSG 5240 Advanced Pharmacology Midterm Exam Practice Study Guide is
designed as a rigorous educational resource for graduate-level nursing pharmacology
preparation. It focuses on advanced application of pharmacokinetic and
pharmacodynamic principles, medication safety, drug interactions, adverse-effect
recognition, individualized therapy, and clinical decision-making. Questions
emphasize complex patient scenarios rather than simple memorization, requiring
learners to interpret laboratory findings, evaluate therapeutic responses, recognize
contraindications, prioritize interventions, and select appropriate pharmacologic
strategies. The practice set incorporates concepts commonly encountered in advanced
pharmacology coursework, including cardiovascular, endocrine, antimicrobial,
autonomic, and central nervous system agents. It is intended strictly as a study
resource to reinforce concepts and clinical reasoning for an NSG 5240 Advanced
Pharmacology midterm; it does not reproduce or claim to reproduce any actual
examination questions.
QUESTION 1.
,A 68-year-old patient with chronic kidney disease has been prescribed a medication
that is primarily eliminated unchanged by the kidneys. After several weeks of
therapy, the patient develops increasing sedation despite receiving the same dose
that was previously well tolerated. The patient's serum creatinine has increased
substantially from baseline. Which pharmacokinetic change most directly explains
the patient's increased drug exposure?
A. Increased hepatic first-pass metabolism
B. Decreased renal clearance resulting in an increased elimination half-life
C. Increased plasma protein binding causing accelerated elimination
D. Increased volume of distribution caused by reduced renal perfusion
🔴 Correct Answer: B. Decreased renal clearance resulting in an increased
elimination half-life
🔵 Explanation: Reduced renal clearance decreases the rate at which the drug is
eliminated, increasing its elimination half-life and allowing accumulation with
repeated dosing. This can produce progressive toxicity even when the prescribed dose
has not changed. Increased first-pass metabolism would generally reduce systemic
exposure, while increased protein binding does not explain the primary mechanism in
this scenario.
QUESTION 2.
A patient receiving warfarin for prevention of thromboembolism is started on a
medication that inhibits CYP2C9, the major enzyme responsible for metabolism of
the more potent S-enantiomer of warfarin. Three days later, the patient's INR has
increased substantially. Which interpretation is most appropriate?
A. The new medication has increased renal excretion of warfarin
B. Warfarin absorption has been reduced, producing a falsely elevated INR
C. The interaction is clinically insignificant because only the R-enantiomer is
pharmacologically active
D. CYP2C9 inhibition has reduced warfarin metabolism and increased anticoagulant
effect
🔴 Correct Answer: D. CYP2C9 inhibition has reduced warfarin metabolism and
increased anticoagulant effect
,🔵 Explanation: Inhibition of CYP2C9 decreases metabolism of S-warfarin, increasing
systemic exposure and anticoagulant activity. The resulting elevation in INR increases
bleeding risk and warrants prompt clinical assessment and medication-management
decisions. The interaction is clinically important because S-warfarin contributes
substantially to warfarin's anticoagulant effect.
QUESTION 3.
A patient with hypertension and heart failure is prescribed an ACE inhibitor. Two
weeks later, the patient reports persistent dry cough but has no dyspnea, fever, or
evidence of pulmonary infection. Which mechanism best explains this adverse
effect?
A. Increased pulmonary bradykinin concentration caused by ACE inhibition
B. Direct stimulation of bronchial β2 receptors
C. Increased pulmonary aldosterone secretion
D. Histamine depletion within airway mast cells
🔴 Correct Answer: A. Increased pulmonary bradykinin concentration caused by
ACE inhibition
🔵 Explanation: ACE participates in the degradation of bradykinin, so ACE inhibition
can increase bradykinin concentrations in pulmonary tissue and produce a persistent
nonproductive cough. The symptom is a recognized class effect and is not caused by
β2-receptor stimulation or histamine depletion. If clinically significant, an angiotensin
receptor blocker may be considered as an alternative because it does not directly
inhibit bradykinin degradation.
QUESTION 4.
A patient with type 2 diabetes mellitus and established atherosclerotic
cardiovascular disease has inadequate glycemic control despite metformin therapy.
The clinician is selecting an additional agent and wants to minimize hypoglycemia
while providing cardiovascular benefit. Which pharmacologic approach is most
appropriate?
A. Add a sulfonylurea as first-line cardiovascular risk-reduction therapy
B. Add a short-acting insulin secretagogue regardless of cardiovascular risk
, C. Consider a GLP-1 receptor agonist with demonstrated cardiovascular benefit
D. Discontinue metformin and initiate a thiazolidinedione solely to reduce
cardiovascular risk
🔴 Correct Answer: C. Consider a GLP-1 receptor agonist with demonstrated
cardiovascular benefit
🔵 Explanation: In appropriate patients with type 2 diabetes and established
atherosclerotic cardiovascular disease, certain GLP-1 receptor agonists have
demonstrated cardiovascular risk-reduction benefits and have a relatively low intrinsic
risk of hypoglycemia when used without insulin or insulin secretagogues.
Sulfonylureas can cause clinically significant hypoglycemia and do not provide the
same cardiovascular outcome advantages. Therapy must still be individualized
according to renal function, adverse-effect profile, comorbidities, and treatment goals.
QUESTION 5.
A patient receiving vancomycin for a serious bacterial infection has a declining
estimated glomerular filtration rate. The patient's antimicrobial therapy must
continue, but the clinician is concerned about accumulation and nephrotoxicity.
Which intervention best demonstrates pharmacokinetic-based medication
management?
A. Increase the dose because renal impairment reduces tissue penetration
B. Adjust the dosing regimen based on renal function and appropriate therapeutic
drug monitoring
C. Maintain the original regimen because vancomycin is eliminated primarily
through hepatic metabolism
D. Discontinue all laboratory monitoring once the patient becomes afebrile
🔴 Correct Answer: B. Adjust the dosing regimen based on renal function and
appropriate therapeutic drug monitoring
🔵 Explanation: Vancomycin is predominantly eliminated by the kidneys, so declining
renal function can increase exposure and toxicity risk. Dosing and monitoring should
be individualized using renal function and an appropriate pharmacokinetic
monitoring strategy. Maintaining the original regimen without reassessment may
